- Oops!Something went wrong.Please try again later.
Shares of Edwards Lifesciences (NYSE:EW) moved higher by 3.5% in after-market trading after the company reported Q2 results.
Earnings per share decreased 75.36% year over year to $0.34, which beat the estimate of $0.17.
Revenue of $925,000,000 declined by 14.90% year over year, which beat the estimate of $789,420,000.
The upcoming fiscal year's EPS expected to be between $1.75 and $1.95.
Q3 revenue expected between $4,000,000,000 and $4,500,000,000.
Details Of The Call
Date: Jul 23, 2020
Time: 05:00 PM
52-week high: $247.64
52-week low: $66.23
Price action over last quarter: Up 8.39%
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.